Memorial Sloan-Kettering Cancer Center (MSKCC) was founded in 1884 and is located in New York City, dedicated solely to cancer treatment, research, and education. As a leading cancer treatment facility, it offers a comprehensive range of services, including outpatient care, clinical trials, and advanced surgical and radiation therapies.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| MSKCC 2.96% 2050-01-01 USDMemorial Sloan-Kettering Cancer Center | United States | 2050-01-01 | 2.955 | 5.64 |
| MSKCC 4.13% 2052-07-01 USDMemorial Sloan-Kettering Cancer Center | United States | 2052-07-01 | 4.125 | 5.52 |
| MSKCC 4.20% 2055-07-01 USDMemorial Sloan-Kettering Cancer Center | United States | 2055-07-01 | 4.200 | 5.51 |
| MSKCC 5.00% 2042-07-01 USDMemorial Sloan-Kettering Cancer Center | United States | 2042-07-01 | 5.000 | 5.32 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
MSKCC began issuing bonds in the late 1990s to fund expansions and enhance their clinical capabilities. Notably, their 2017 bond issuance raised $150 million for facility upgrades and research initiatives, reflecting strong investor confidence indicated by current yields that compare favorably within the healthcare sector. The bonds typically feature tax-exempt status, appealing to retail investors seeking stable income from municipal securities, while recent reports indicate an ongoing commitment to financing innovative cancer therapies through further bond offerings.